LLYZ

Defiance Daily Target 2X Short LLY ETF

$9.61
+0.00%
Market closed. Last update: 10:57 PM ET

📎 Investment Objective

The Defiance Daily Target 2X Short LLY ETF (LLYZ) seeks to provide daily investment results that correspond to twice the inverse (or opposite) of the daily performance of the common stock of Eli Lilly and Company (LLY).

Overview

ETF tracking Defiance Daily Target 2X Short LLY ETF

Category Inverse
Issuer Other
Inception Date 2025-09-03
Market Cap N/A
Average Volume N/A
Dividend Yield N/A
52-Week Range $9.61 - $21.03
VWAP $9.70

Performance

Loading performance data...

Price Chart

Investment Summary

📎 Investment Objective

The Defiance Daily Target 2X Short LLY ETF (LLYZ) seeks to provide daily investment results that correspond to twice the inverse (or opposite) of the daily performance of the common stock of Eli Lilly and Company (LLY).

🎯 Investment Strategy

The ETF uses a range of financial instruments, such as swap agreements and futures contracts, to achieve its daily inverse 2x target exposure to the underlying LLY stock. It does not seek to achieve its stated investment objective over periods longer than a single day.

✨ Key Features

  • Provides 2x daily inverse exposure to Eli Lilly and Company stock performance
  • Designed for short-term, tactical trading rather than long-term investment
  • Employs derivatives to achieve its daily target exposure
  • Has a very low asset base and expense ratio of 0.00%

⚠️ Primary Risks

  • Significant daily rebalancing risk due to the 2x leverage, which can lead to returns that do not match the inverse of the underlying over longer periods
  • Potential for large losses if the underlying stock rises in value
  • Liquidity risk due to the low asset base and trading volume
  • Counterparty risk associated with the derivative instruments used

👤 Best For

This ETF is best suited for experienced, sophisticated traders who understand the risks of leveraged and inverse products and are looking for short-term, tactical exposure to the inverse performance of Eli Lilly's stock. It is not recommended for long-term buy-and-hold investors.